Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping reviewTiago Costa de Pádua, Andrea Necchi, Marco Moschini et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 29
P3.03-019 Activity of PARP Inhibitor in NSCLC with Germline and Somatic Mutation and in Silico Chemotherapy LethalityCarmélia Maria Noia Barreto, N Yamaguchi, M.F. Manfrivato et al.|Journal of Thoracic Oncology|2017Cited by 0